SCHEMBL8003589

SCHEMBL8003589

COc1ccc(S(=O)(=O)N(CC(=O)NO)Cc2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BMP1 P13497 4/20 1.00
MEP1B Q16820 3/20 0.73
MMP1 P03956 6/20 0.70
MMP3 P08254 5/20 0.67
MMP13 P45452 5/20 0.62
MMP2 P08253 4/20 0.62
MMP9 P14780 4/20 0.62
ADAM10 O14672 1/20 0.62
ADAM17 P78536 1/20 0.62
MEP1A Q16819 1/20 0.62
MMP8 P22894 5/20 0.61
MMP7 P09237 2/20 0.61
MMP12 P39900 2/20 0.61
CA2 P00918 2/20 0.58
CA1 P00915 1/20 0.57
MMP14 P50281 1/20 0.57
MMP16 P51512 1/20 0.57
CA9 Q16790 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7348906 0.91 MEP1B (0.86) BMP1MEP1BMMP1MMP3MMP13
SCHEMBL6421526 0.88 BMP1 (0.78) BMP1MEP1BMMP1MMP3MMP13
SCHEMBL6411677 0.86 MEP1B (0.79) BMP1MEP1BMMP1MMP3MMP13
SCHEMBL5577038 0.85 MEP1B (0.78) BMP1MEP1BMMP1MMP3MMP13
SCHEMBL7421418 0.85 BMP1 (0.74) BMP1MEP1BMMP1MMP3MMP13
SCHEMBL7338644 0.85 MEP1B (0.81) BMP1MEP1BMMP1MMP3MMP13
SCHEMBL2515648 0.85 BMP1 (0.73) BMP1MEP1BMMP1MMP3MMP13
SCHEMBL26772450 0.84 MEP1B (1.00) BMP1MEP1BMMP1MMP3MMP13
Hydrochloric Acid SCHEMBL7350033 0.84 BMP1 (0.73) BMP1MEP1BMMP1MMP3MMP13
SCHEMBL7350511 0.83 MEP1B (0.78) BMP1MEP1BMMP1MMP3MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357139-A1 SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS Artizan Biosciences, Inc. 2023-11-09 US disclosed
EP-0845987-A4 C-PROTEINASE INHIBITORS FOR THE TREATMENT OF DISORDERS RELATED TO THE OVERPRODUCTION OF COLLAGEN FIBROGEN INC (US) 2000-05-24 EP disclosed
EP-0845987-A1 C-PROTEINASE INHIBITORS FOR THE TREATMENT OF DISORDERS RELATED TO THE OVERPRODUCTION OF COLLAGEN FIBROGEN, INC. (US) 1998-06-10 EP disclosed
WO-1997005865-A1 C-PROTEINASE INHIBITORS FOR THE TREATMENT OF DISORDERS RELATED TO THE OVERPRODUCTION OF COLLAGEN FIBROGEN, INC. (US) 1997-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357139-A1 SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS FABP2, APC, SI BMP1 3685/4885MEP1B 3750/4885MMP1 643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.